Prostaglandin E1 treatment in patent ductus arteriosus dependent congenital heart defects

Gyula Tálosi, M. Katona, Katalin Rácz, Erzsébet Kertész, Beáta Onozó, S. Túri

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Prostaglandin E1 (PGE1) treatment can be life saving in patients suffering from ductus dependent congenital heart defect. We analyzed the indications and side-effects of PGE1 therapy over a five-year period. The purpose of the study was also to examine whether a change in serum electrolyte levels could be detected. Forty-nine patients were treated with PGE1 during this period. PGE1 treatment was indicated by ductus dependent systemic circulation in 16 cases, ductus dependent pulmonary circulation in 17 cases, transposition of the great arteries in 13 cases and pulmonary hypertension (persistent fetal circulation) in three cases. As early side-effects of the treatment, fever occurred in 27/49 cases while apnoea was observed in 15 patients. In a one-week-old neonate with coarctation of the aorta grade III intraventricular hemorrhage developed. A mild decrease of sodium, potassium and chloride levels and a slight shift of pH levels toward metabolic alkalosis could be detected after one day and one week of PGE1 treatment. Because of these side-effects of PGE1 patients should be monitored in an intensive care unit. According to our observations electrolyte levels may exhibit a slight decrease; however, in the case of a short-term therapy extra salt supplementation is not necessary.

Original languageEnglish
Pages (from-to)368-374
Number of pages7
JournalJournal of Perinatal Medicine
Volume32
Issue number4
DOIs
Publication statusPublished - 2004

Fingerprint

Patent Ductus Arteriosus
Congenital Heart Defects
Alprostadil
Electrolytes
Therapeutics
Persistent Fetal Circulation Syndrome
Alkalosis
Transposition of Great Vessels
Aortic Coarctation
Pulmonary Circulation
Potassium Chloride
Apnea
Pulmonary Hypertension
Sodium Chloride
Intensive Care Units
Fever
Salts
Newborn Infant
Hemorrhage
Serum

Keywords

  • Congenital heart defect
  • Ductus arteriosus Botalli
  • Neonate
  • Prostaglandin E

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Pediatrics, Perinatology, and Child Health

Cite this

Prostaglandin E1 treatment in patent ductus arteriosus dependent congenital heart defects. / Tálosi, Gyula; Katona, M.; Rácz, Katalin; Kertész, Erzsébet; Onozó, Beáta; Túri, S.

In: Journal of Perinatal Medicine, Vol. 32, No. 4, 2004, p. 368-374.

Research output: Contribution to journalArticle

Tálosi, Gyula ; Katona, M. ; Rácz, Katalin ; Kertész, Erzsébet ; Onozó, Beáta ; Túri, S. / Prostaglandin E1 treatment in patent ductus arteriosus dependent congenital heart defects. In: Journal of Perinatal Medicine. 2004 ; Vol. 32, No. 4. pp. 368-374.
@article{15b098567a56441688bb47782c641f18,
title = "Prostaglandin E1 treatment in patent ductus arteriosus dependent congenital heart defects",
abstract = "Prostaglandin E1 (PGE1) treatment can be life saving in patients suffering from ductus dependent congenital heart defect. We analyzed the indications and side-effects of PGE1 therapy over a five-year period. The purpose of the study was also to examine whether a change in serum electrolyte levels could be detected. Forty-nine patients were treated with PGE1 during this period. PGE1 treatment was indicated by ductus dependent systemic circulation in 16 cases, ductus dependent pulmonary circulation in 17 cases, transposition of the great arteries in 13 cases and pulmonary hypertension (persistent fetal circulation) in three cases. As early side-effects of the treatment, fever occurred in 27/49 cases while apnoea was observed in 15 patients. In a one-week-old neonate with coarctation of the aorta grade III intraventricular hemorrhage developed. A mild decrease of sodium, potassium and chloride levels and a slight shift of pH levels toward metabolic alkalosis could be detected after one day and one week of PGE1 treatment. Because of these side-effects of PGE1 patients should be monitored in an intensive care unit. According to our observations electrolyte levels may exhibit a slight decrease; however, in the case of a short-term therapy extra salt supplementation is not necessary.",
keywords = "Congenital heart defect, Ductus arteriosus Botalli, Neonate, Prostaglandin E",
author = "Gyula T{\'a}losi and M. Katona and Katalin R{\'a}cz and Erzs{\'e}bet Kert{\'e}sz and Be{\'a}ta Onoz{\'o} and S. T{\'u}ri",
year = "2004",
doi = "10.1515/JPM.2004.069",
language = "English",
volume = "32",
pages = "368--374",
journal = "Journal of Perinatal Medicine",
issn = "0300-5577",
publisher = "Walter de Gruyter GmbH & Co. KG",
number = "4",

}

TY - JOUR

T1 - Prostaglandin E1 treatment in patent ductus arteriosus dependent congenital heart defects

AU - Tálosi, Gyula

AU - Katona, M.

AU - Rácz, Katalin

AU - Kertész, Erzsébet

AU - Onozó, Beáta

AU - Túri, S.

PY - 2004

Y1 - 2004

N2 - Prostaglandin E1 (PGE1) treatment can be life saving in patients suffering from ductus dependent congenital heart defect. We analyzed the indications and side-effects of PGE1 therapy over a five-year period. The purpose of the study was also to examine whether a change in serum electrolyte levels could be detected. Forty-nine patients were treated with PGE1 during this period. PGE1 treatment was indicated by ductus dependent systemic circulation in 16 cases, ductus dependent pulmonary circulation in 17 cases, transposition of the great arteries in 13 cases and pulmonary hypertension (persistent fetal circulation) in three cases. As early side-effects of the treatment, fever occurred in 27/49 cases while apnoea was observed in 15 patients. In a one-week-old neonate with coarctation of the aorta grade III intraventricular hemorrhage developed. A mild decrease of sodium, potassium and chloride levels and a slight shift of pH levels toward metabolic alkalosis could be detected after one day and one week of PGE1 treatment. Because of these side-effects of PGE1 patients should be monitored in an intensive care unit. According to our observations electrolyte levels may exhibit a slight decrease; however, in the case of a short-term therapy extra salt supplementation is not necessary.

AB - Prostaglandin E1 (PGE1) treatment can be life saving in patients suffering from ductus dependent congenital heart defect. We analyzed the indications and side-effects of PGE1 therapy over a five-year period. The purpose of the study was also to examine whether a change in serum electrolyte levels could be detected. Forty-nine patients were treated with PGE1 during this period. PGE1 treatment was indicated by ductus dependent systemic circulation in 16 cases, ductus dependent pulmonary circulation in 17 cases, transposition of the great arteries in 13 cases and pulmonary hypertension (persistent fetal circulation) in three cases. As early side-effects of the treatment, fever occurred in 27/49 cases while apnoea was observed in 15 patients. In a one-week-old neonate with coarctation of the aorta grade III intraventricular hemorrhage developed. A mild decrease of sodium, potassium and chloride levels and a slight shift of pH levels toward metabolic alkalosis could be detected after one day and one week of PGE1 treatment. Because of these side-effects of PGE1 patients should be monitored in an intensive care unit. According to our observations electrolyte levels may exhibit a slight decrease; however, in the case of a short-term therapy extra salt supplementation is not necessary.

KW - Congenital heart defect

KW - Ductus arteriosus Botalli

KW - Neonate

KW - Prostaglandin E

UR - http://www.scopus.com/inward/record.url?scp=3543025736&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3543025736&partnerID=8YFLogxK

U2 - 10.1515/JPM.2004.069

DO - 10.1515/JPM.2004.069

M3 - Article

C2 - 15346826

AN - SCOPUS:3543025736

VL - 32

SP - 368

EP - 374

JO - Journal of Perinatal Medicine

JF - Journal of Perinatal Medicine

SN - 0300-5577

IS - 4

ER -